Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

[1]  A. Giuliano,et al.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial , 2017, JAMA.

[2]  L. Rydén,et al.  Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial , 2017, BMC Cancer.

[3]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  A. Luini,et al.  Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[6]  A. Luini,et al.  Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[9]  U. Veronesi,et al.  Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). , 2012, Breast.

[10]  A. Luini,et al.  Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? , 2012, Breast Cancer Research and Treatment.

[11]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[12]  E. Rutgers,et al.  UvA-DARE ( Digital Academic Repository ) Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS , 2010 .

[13]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[14]  A. Giuliano,et al.  Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer. , 2010, Archives of surgery.

[15]  E. Winer,et al.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Cody,et al.  The Risk of Axillary Relapse After Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable With That of Axillary Lymph Node Dissection: A Follow-up Study of 4008 Procedures , 2004, Annals of surgery.

[17]  Mark C Kelley,et al.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer. , 2004, American journal of surgery.

[18]  P. Bult,et al.  Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure , 2001, Breast Cancer Research and Treatment.

[19]  L. Strobbe,et al.  Axillary Recurrence After a Negative Sentinel NodeBiopsy for Breast Cancer: Incidence and Clinical Significance , 2004, Annals of Surgical Oncology.

[20]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[21]  T. Nims,et al.  Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? , 2001, American journal of surgery.

[22]  A. Luini,et al.  Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma , 2001, Cancer.

[23]  J. Donohue,et al.  Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Foster,et al.  The sentinel node in breast cancer--a multicenter validation study. , 1998, The New England journal of medicine.

[25]  I Taylor,et al.  Assessment of morbidity from complete axillary dissection. , 1992, British Journal of Cancer.

[26]  S. Huchcroft,et al.  Arm function after axillary dissection for breast cancer: A pilot study to provide parameter estimates , 1992, Journal of surgical oncology.

[27]  P. O'dwyer.  Axillary dissection in primary breast cancer. , 1991, BMJ.

[28]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[29]  M. Morrow,et al.  Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma? , 1984, Cancer.